Profile data is unavailable for this security.
About the company
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
- Revenue in USD (TTM)183.40m
- Net income in USD-79.99m
- Incorporated1990
- Employees229.00
- LocationGeron Corp919 East Hillsdale Boulevard, Suite 250FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 473-7700
- Fax+1 (302) 655-5049
- Websitehttps://www.geron.com/
